CLINICAL TRIALS PROFILE FOR BEMCENTINIB

Clinical Trials for Bemcentinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02424617 ↗	A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	Completed	BerGenBio AS	Phase 1/Phase 2	A Phase I/2 multi-center open-label study of BGB324 (bemcentinib) in combination with erlotinib in participants with Stage IIIb or Stage IV non-small cell lung cancer. Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
NCT02424617 ↗	A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	Completed	BerGenBio ASA	Phase 1/Phase 2	A Phase I/2 multi-center open-label study of BGB324 (bemcentinib) in combination with erlotinib in participants with Stage IIIb or Stage IV non-small cell lung cancer. Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
NCT02488408 ↗	A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS	Active, not recruiting	BerGenBio AS	Phase 1/Phase 2	A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a combination with cytarabine or decitabine in AML participants. Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.
NCT02488408 ↗	A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS	Active, not recruiting	BerGenBio ASA	Phase 1/Phase 2	A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a combination with cytarabine or decitabine in AML participants. Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.
NCT03184558 ↗	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC	Terminated	Merck Sharp & Dohme Corp.	Phase 2	This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The primary objective is objective response rate.
NCT03184558 ↗	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC	Terminated	BerGenBio ASA	Phase 2	This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The primary objective is objective response rate.

Clinical Trial Conditions for Bemcentinib

Condition Name

Condition Name for
Intervention	Trials
Acute Myeloid Leukemia	2
Inflammatory Breast Cancer Stage IV	1
Low-risk Myelodysplastic Syndrome	1
Lung Cancer Metastatic	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Lung Neoplasms	3
Carcinoma, Non-Small-Cell Lung	2
Preleukemia	2
Myelodysplastic Syndromes	2

Clinical Trial Locations for Bemcentinib

Trials by Country

Trials by Country for
Location	Trials
United States	21
India	6
South Africa	4
United Kingdom	4
Spain	3

Trials by US State

Trials by US State for
Location	Trials
Texas	3
Pennsylvania	2
New Hampshire	2
Michigan	2
California	2

Clinical Trial Progress for Bemcentinib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	5
Phase 1/Phase 2	4
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Recruiting	4
Active, not recruiting	2
Completed	2

Clinical Trial Sponsors for Bemcentinib

Sponsor Name

Sponsor Name for
Sponsor	Trials
BerGenBio ASA	10
Merck Sharp & Dohme Corp.	3
BerGenBio AS	2

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	20
Other	10
NIH	1